•Unfortunately, no drug treatment has been shown to benefit patients with progressive supranuclear palsy (PSP) more than modestly or briefly. The multiplicity of neuronal systems and synaptic physiologies that degenerate in this disorder makes a neurotransmitter-specific approach, such as neurotransmitter replacement or reuptake inhibition, unlikely to succeed. Nevertheless, some of these are worth trying in nearly every patient with PSP. Useful drug treatment may ultimately take the form of enhancers of mitochondrial energy metabolism, inducers of endogenous neurotrophic factors, and, even further in the future, inhibitors of tau aggregation or regulators of alternative splicing.
•The neurologist familiar with PSP can assist patients and their family by providing prognostic information, by avoiding unnecessary diagnostic tests, and by prescribing measures to minimize aspiration and falling, the two most dangerous complications of PSP.
Unable to display preview. Download preview PDF.
References and Recommended Reading
- 3.Schrag A, Ben-Shlomo Y, Quinn N: Prevalence of PSP and MSA: a cross-sectional study. Lancet 1999, 354:1771–1772. These authors scrutinized several British general practitioners’ records, extracting and examinging all patients whose previous medical encounters offered even the slightest suggestion of PSP. Of the six such cases that met PSP diagnositc criteria on the authors’ examination, none had previously been diagnosed with PSP. This demonstrates that most PSP remains undiagnosed.PubMedCrossRefGoogle Scholar
- 6.Golbe LI: Progressive supranuclear palsy. In Movement Disorders: Neurologic Principles and Practice. Edited by Watts R, Koller W. New York: McGraw-Hill; 1997:279–295.Google Scholar
- 7.Golbe LI: Progressive supranuclear palsy. In Differential Diagnosis and Treatment of Movement Disorders. Edited by Tolosa E, Koller WC, Gershanik OS. Boston: Butterworth Heinemann; 1998:27–38.Google Scholar
- 8.Baker M, Litvan I, Houlden H, et al.: Association of an extended haplotype in the tau gene with PSP. Hum Mol Genet 1999, 8:711–715. This and the next reference (reference ) show that a genetic variant in or near the tau gene at chromosome 17q21 is present in nearly all patients with PSP, but in only about half of control individuals. This has since prompted searches for the precise genetic defect and for the other factors that are necessary, but not individually sufficient to cause the disease.PubMedCrossRefGoogle Scholar
- 9.Higgins JJ, Adler RL, Loveless JM: Mutational analysis of the tau gene in PSP. Neurology 1999, 53:1421–1424. This and the previous reference (reference ) show that a genetic variant in or near the tau gene at chromosome 17q21 is present in nearly all patients with PSP, but in only about half of control individuals. This has since prompted searches for the precise genetic defect and for the other factors that are necessary, but not individually sufficient to cause the disease.PubMedGoogle Scholar
- 18.Lepore FE: PSP. In Neuro-Ophthalmological Disorders: Diagnostic Workup and Management. Edited by Tusa RJ, Newman SA. New York: Marcel Dekker; 2001.Google Scholar